PF-00299804 (PF299) patient (pt)-reported outcomes (PROs) and efficacy in adenocarcinoma (adeno) and nonadeno non-small cell lung cancer (NSCLC): A phase (P) II trial in advanced NSCLC after failure of chemotherapy (CT) and erlotinib (E)

被引：33
|
作者：
Campbell, A.
Reckamp, K. L.
Camidge, D. R.
Giaccone, G.
Gadgeel, S. M.
Khuri, F. R.
Engelman, J. A.
Denis, L. J.
O'Connell, J. P.
Janne, P. A.
机构：
[1] Pfizer Inc, New London, CT USA
[2] City Hope Natl Med Ctr, Duarte, CA USA
[3] Univ Colorado Denver, Aurora, CO USA
[4] NCI, Bethesda, MD 20892 USA
[5] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
[6] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[7] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[8] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.7596
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7596
引用
收藏
页数：1
相关论文
共 50 条
  • [1] PF-00299804 (PF299) in Asian patients (pts) with non-small cell lung cancer (NSCLC) refractory to chemotherapy (CT) and erlotinib (E) or gefitinib (G): A phase (P) I/II study
    Park, K.
    Heo, D. S.
    Cho, B.
    Kim, D.
    Ahn, M.
    Lee, S.
    Millham, R. A.
    Campbell, A.
    Zhang, H.
    Kim, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] Efficacy and safety of PF-00299804 (PF299) in patients (pt) with advanced NSCLC after failure of at least one prior chemotherapy regimen and prior treatment with erlotinib (E): A two-arm, phase II trial
    Janne, P. A.
    Reckamp, K.
    Koczywas, M.
    Engelman, J. A.
    Camidge, D. R.
    Rajan, A.
    Khuri, F.
    Liang, J. Q.
    O'Connell, J.
    Giaccone, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [3] A phase 2 trial of PF-00299804 (PF299), an oral irreversible HER tyrosine kinase inhibitor (TKI), in patients (pts) with advanced NSCLC after failure of prior chemotherapy and erlotinib: preliminary efficacy and safety results
    Janne, Pasi A.
    Reckamp, Karen
    Koczywas, Marianna
    Camidge, David R.
    Engelman, Jeffery A.
    Khuri, Fadlo
    Rajan, Arun
    Gadgeel, Shirish
    Taylor, Ian
    Liang, Jane
    O'Connell, Joseph
    Giaccone, Giuseppe
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S293 - S294
  • [4] Efficacy and safety of PF299804 versus erlotinib (E): A global, randomized phase II trial in patients (pts) with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy (CT)
    Boyer, M. J.
    Blackhall, F. H.
    Park, K.
    Barrios, C. H.
    Krzakowski, M. J.
    Taylor, I.
    Liang, J. Q.
    Denis, L. J.
    O'Connell, J. P.
    Ramalingam, S. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
  • [5] PATIENT REPORT OF DACOMITINIB (PF-00299804)-ASSOCIATED SYMPTOM AND HRQOL BENEFIT IN PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Doherty, Jim P.
    Reckamp, Karen L.
    Connell, Joseph O.
    Letrent, Stephen
    Ramalingam, Suresh S.
    Boyer, Michael
    Jaenne, Pasi A.
    Park, Keunchil
    Kim, Dong-Wan
    Gadgeel, Shirish
    Bottomley, Andrew
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S906 - S906
  • [6] ARCHER: A RANDOMIZED DOUBLE-BLINDED PHASE III STUDY OF DACOMITINIB (PF-00299804) VERSUS ERLOTINIB FOR ADVANCED (ADV) NON-SMALL CELL LUNG CANCER (NSCLC)
    Antic, V.
    Boyer, M.
    Janne, P.
    Mok, T.
    O'Byrne, K.
    Paz-Ares, L.
    Ramalingam, S. S.
    Liang, J.
    Taylor, I.
    Letrent, S.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S67 - S67
  • [7] ARCHER: Dacomitinib (D; PF-00299804) versus erlotinib (E) for advanced (adv) non-small cell lung cancer (NSCLC)-A randomized double-blind phase III study.
    Boyer, Michael J.
    Janne, Pasi A.
    Mok, Tony
    O'Byrne, Kenneth John
    Paz-Ares, Luis G.
    Ramalingam, Suresh S.
    Liang, Jane Q.
    Taylor, Ian
    Campbell, Alicyn
    O'Connell, Joseph P.
    Letrent, Stephen P.
    Antic, Vladan
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] EVALUATION OF SYMPTOM IMPACT OF DACOMITINIB (PF-00299804) VS ERLOTINIB IN PATIENTS WITH ADVANCED NSCLC AFTER CHEMOTHERAPY FAILURE: RESULTS FROM A PHASE 2 RANDOMIZED CLINICAL TRIAL
    O'Connell, J.
    Bottomley, A.
    Ramalingam, S. S.
    Boyer, M.
    Park, K.
    Blackhall, F.
    Mundayat, R.
    Campbell, A.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S60 - S61
  • [9] OVERALL SURVIVAL (OS) RESULTS OF A RANDOMIZED PHASE 2 TRIAL OF PF299804 VERSUS ERLOTINIB IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) AFTER FAILURE OF CHEMOTHERAPY
    Boyer, Michael
    Blackhall, Fiona H.
    Barrios, Carlos H.
    Frank, Richard C.
    Heo, Deo Seog
    Park, Keunchil
    Rosell, Rafael
    Talbot, Denis C.
    Taylor, Ian C.
    Liang, Jane
    Campbell, Alicyn K.
    O'Connell, Joseph
    Ramalingam, Suresh
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S318 - S319
  • [10] Phase II trial of erlotinib maintenance therapy after platinun-based chemotherapy in advanced non-small cell lung cancer (NSCLC)
    Cobo, M.
    Martinez, J.
    Montesa, A.
    Gil-Calle, S.
    Villar-Chamorro, E.
    Ales, I.
    Gutierrez, V.
    Duran, G.
    Carabantes-Ocon, F.
    Benavides, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345